~ Buy the SEZABY (phenobarbital sodium) Drug Profile, 2024 PDF Report in the Report Store ~

SEZABY Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Sezaby, and what generic alternatives are available?

Sezaby is a drug marketed by Sun Pharm Inds Inc and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in one country.

The generic ingredient in SEZABY is phenobarbital sodium. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the phenobarbital sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Sezaby

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be November 17, 2029. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for SEZABY?
What are the global sales for SEZABY?
What is Average Wholesale Price for SEZABY?

Summary for SEZABY

International Patents:	2
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for SEZABY
What excipients (inactive ingredients) are in SEZABY?	SEZABY excipients list
DailyMed Link:	SEZABY at DailyMed

Drug patent expirations by year for SEZABY

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SEZABY

Generic Entry Date for SEZABY^: ⤷ Sign Up* Constraining patent/regulatory exclusivity: TREATMENT OF NEONATAL SEIZURES IN TERM AND PRETERM INFANTS NDA: 215910 Dosage: POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for SEZABY

SEZABY is protected by one US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of SEZABY is ⤷ Sign Up.

This potential generic entry date is based on TREATMENT OF NEONATAL SEIZURES IN TERM AND PRETERM INFANTS.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting SEZABY

Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF TREATING NEONATAL SEIZURES

FDA Regulatory Exclusivity protecting SEZABY

TREATMENT OF NEONATAL SEIZURES IN TERM AND PRETERM INFANTS
Exclusivity Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	SEZABY	phenobarbital sodium	POWDER;INTRAVENOUS	215910-001	Nov 17, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
Sun Pharm Inds Inc	SEZABY	phenobarbital sodium	POWDER;INTRAVENOUS	215910-001	Nov 17, 2022		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for SEZABY

See the table below for patents covering SEZABY around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
World Intellectual Property Organization (WIPO)	2023281441		⤷ Sign Up
World Intellectual Property Organization (WIPO)	2023175542		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration